Transition Therapeutics' management team has a proven track record in moving products from the discovery stage and rapidly moving products through the clinic.
Dr. Tony CruzChief Executive Officer
Dr. Cruz is one of the founders of Transition Therapeutics and has held the position of Chief Executive Officer of Transition Therapeutics since its inception in July 1998. Dr. Cruz was a Co-Founder, Vice-President and Director at Angiotech Pharmaceuticals Inc. Dr. Cruz has been a Senior Scientist at Mount Sinai Hospital since 1995 and was the CEO and President of the Canadian Arthritis Network until 2001. He has also served as a consultant for biotechnology companies and investment firms.
Elie FarahPresident & Chief Financial Officer
Mr. Farah joined Transition in May, 2005 as the CFO and VP Corporate Development, and he was appointed President and CFO in July, 2008. Mr. Farah brings a wealth of experience from his time at Boehringer Ingelheim, an international pharmaceutical company based in Germany. Mr. Farah headed their global mergers and acquisitions initiative where he managed, executed and oversaw a number of strategic transactions across Europe and the Americas. He brings expertise in technology and company valuations, integration of management teams, and licensing and partnership of technologies with large pharma organizations. Prior to working at Boehringer Ingelheim, Mr. Farah held a number of positions at Price Waterhouse in Canada.
Dr. Aleksandra PastrakVP of Research and Medical Officer
Dr. Pastrak has been with Transition since 1999 and assumed the role of VP, Research in May, 2005. With her expertise in medicine and pharmacology, she has made an invaluable contribution to the development of our clinical programs for various therapeutic products. Dr. Pastrak holds an MD from the School of Medicine at the University of Belgrade and M.Sc. and Ph.D. degrees in Clinical Pharmacology from the University of Toronto.
Mr. Carl DamianiVP Business Development
Mr. Damiani has been with Transition since 2003 and was appointed Vice-President, Business Development in December 2007. Mr. Damiani is a key member of the Company's management team and is responsible for a broad range of activities, including licensing and intellectual property strategies. Prior to joining Transition, Mr. Damiani led multiple successful start-up businesses in the biotech and services industries.
